Viatris Reports 6% Revenue Decline and $4.6 Million Net Loss in Q2 2025

Viatris Inc. reported a decline in financial performance for the second quarter of 2025, with total revenues of $3.58 billion, down 6% from $3.80 billion in the same period last year. Net sales also decreased by 6%, totaling $3.57 billion compared to $3.79 billion in the prior year. The decrease was attributed to divestitures completed in 2024 and the negative impact from the company's Indore manufacturing facility, which faced regulatory challenges. The company recorded a net loss of $4.6 million for the quarter, a significant improvement from a loss of $326.4 million in the previous year.

For the first half of 2025, Viatris reported total revenues of $6.84 billion, an 8% decrease from $7.46 billion in the same period of 2024. The net loss for the six months ended June 30, 2025, was $3.05 billion, compared to a loss of $212.5 million in the prior year. This substantial loss was primarily driven by a goodwill impairment charge of $2.94 billion recorded in the first quarter, reflecting increased business risks and uncertainties in the geopolitical and economic environments.

Strategically, Viatris completed the acquisition of exclusive global development and commercialization rights to two Phase 3 assets from Idorsia in March 2024, which included an upfront payment of $350 million. The company also amended the agreement in February 2025 to gain additional territory rights and reduce contingent milestone payments. Operationally, Viatris continues to face challenges from the FDA's warning letter and import alert related to its Indore facility, which is expected to negatively impact revenues by approximately $500 million for the year.

In terms of market performance, Viatris' Developed Markets segment saw a 9% decline in net sales, while the Greater China segment experienced a 9% increase. The JANZ segment reported a 13% decrease, and the Emerging Markets segment saw a 4% decline. The company’s employee headcount remains approximately 32,000, with operations in over 165 countries. Viatris continues to focus on its strategic initiatives, including potential acquisitions and divestitures, to enhance its market position and financial stability.

Looking ahead, Viatris anticipates ongoing challenges due to regulatory pressures and market conditions but remains committed to its mission of providing high-quality medicines globally. The company expects to leverage its extensive portfolio and operational capabilities to navigate these challenges and drive future growth.